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Abstract
The Hsp90 chaperone machine is required for the folding, activation and/or stabilization of more
than 50 proteins directly related to malignant progression. Hsp90 contains small molecule binding
sites at both its N- and C-terminal domains, however, limited structural and biochemical data
regarding the C-terminal binding site is available. In this report, the small molecule binding site in
the Hsp90 C-terminal domain was revealed by protease fingerprinting and photoaffinity labeling
utilizing LC-MS/MS. The identified site was characterized by generation of a homology model for
hHsp90α using the SAXS open structure of HtpG and docking the bioactive conformation of NB
into the generated model. The resulting model for the bioactive conformation of NB bound to
Hsp90α is presented herein.
Hsp90 is the core component of a chaperone machine that modulates the folding, activation,
and stability of more than 200 substrates. Hsp90 functions by undergoing a series of
conformational changes that are driven by the binding and hydrolysis of ATP, which are
modulated through Hsp90's interactions with a variety of co-chaperones and partner proteins
(reviewed in(1–2)). Because Hsp90-dependent clients are directly associated with all six
hallmarks of cancer(3), Hsp90 is under intense investigation as a pharmacological target for
the treatment of cancer (4–5).
Hsp90 contains drugable sites at both its N- and C-terminal domains. High affinity Hsp90
inhibitors that bind the Hsp90 N-terminal nucleotide binding site are well characterized, as
they have been co-crystallized with this domain (i.e., geldanamycin and radicicol (6–7)). In
fact, several N-terminal inhibitors are currently in clinical trials for the treatment of cancer
(8). In 2000, Neckers and co-workers identified the first C-terminal inhibitor of Hsp90 (9–
10) by demonstrating the ability of the Hsp90 C-terminus to bind novobiocin (NB) (Fig. 1)
and proposed this domain to represent a nucleotide–binding site that allosterically regulates
nucleotide binding at the N-terminus.
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Not only does NB inhibit Hsp90 function by binding to the C-terminus of Hsp90, but related
family members chlorobiocin (CB) and coumermycin A1 also display Hsp90 inhibitory
profiles that are different from those manifested by N-terminal inhibitors (Fig. 1). In
addition, C-terminal inhibitors exhibit unique effects on Hsp90's conformation, activity, and
interactions with co-chaperones and clients (9–12), highlighting this site as a potential target
for Hsp90 modulation. Unfortunately, the mechanism of action for Hsp90 “C-terminal
inhibitors” has not been adequately pursued in large part due to their poor pharmacological
potency (100–700 μM)(9–10, 12–13). Although analogues of NB that exhibit improved
Hsp90-inhibitory and anti-cancer activity (14–19) have been reported, the inability to obtain
co-crystal structures with these molecules bound to the chaperone has hampered further
development.
Crystal structures of yeast Hsp90, its human ER homologue (Grp94), and E. coli homologue
(HtpG) have provided insights into the conformational changes Hsp90 undergoes during the
substrate folding process. In addition, low resolution small-angle X-ray scattering (SAXS)
(20–21) and cryo-electron microscopy studies (22–23) have provided additional evidence in
support of the multiple conformations necessary for folding client substrates. While SAXS
(20–21) and cryo-electron microscopy (22–23) studies have clearly demonstrated the Hsp90
C-terminus to adopt distinct conformations, these structures have not provided the resolution
necessary for structure-based drug design of improved inhibitors. Unfortunately, the
available structures of Hsp90's C-terminal domain and its homologues are similar, and
represent the closed, clamped conformation, in which the apparent binding site is
inaccessible. In addition, as first suggested by Agard and co-workers, Hugel and co-workers
have recently confirmed that the Hsp90 C-terminus undergoes significant conformational
changes and opens across the dimerization domain when the Hsp90 N-terminal ATP binding
site is occupied, providing a potential mechanism for client protein release (24).
To circumvent limitations imposed upon the rational development of NB analogues through
a structure-based approach, the NB binding site located in the Hsp90 C-terminus was sought
after via photolabile NB derivatives, which upon covalent attachment to Hsp90 could aid in
elucidation of the Hsp90 C-terminal binding site. Subsequent refinement of the biologically
active conformation NB bound to Hsp90 could then be derived from the SAXS structure of
HtpG in its open conformation, which allows occupancy of the C-terminus. As revealed by
co-crystal structures of NB bound to closely related enzymes (e.g., DNA gyrase/
topoisomerase(25–26)), the active conformation of NB could then be docked, and subjected
to a ligand-supported refinement followed by a systematic molecular dynamics (MD) based
methodology to identify the binding site for NB and its analogues. Herein, we present our
approach towards elucidation of the Hsp90 C-terminal binding site following this protocol.
RESULTS AND DISCUSSION
Identification of the Hsp90 C-terminal Protease Resistant Core
Binding of NB and chlorobiocin (CB) to the Hsp90 C-terminus protects this domain from
proteolysis by trypsin (12), which is not the case for N-terminal inhibitors, suggesting that
C-terminal occupancy plays a significant role in protein conformation. Surface plasmon
resonance spectroscopy analysis of the binding of chlorobiocin and coumerimycin A1 to full
length Hsp90 and Hsp90CT indicates that the C-terminal domain of Hsp90 binds the
compounds with affinities comparable to the intact, full length protein, suggesting that
truncation does not compromise the structure of the Hsp90's C-terminal binding site (R.L.
Matts, J. R. Manjarrez and K. Szalba, unpublished results). To determine the amino acid
residues that define the CB-bound protease resistant core of Hsp90, a His-tagged Hsp90 C-
terminal construct was digested with V8 protease in the presence and absence of
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chlorobiocin. V8 was chosen because the N- and C-terminal regions of Hsp90 are deficient
in Lys and Arg residues, but rich in Glu and Asp.
Upon SDS-PAGE analysis of Hsp90 C-terminal proteolysis products, four bands were found
resistant to V8 cleavage in samples containing CB that were absent from the control (Fig.
2A). Analysis of the in-gel tryptic digests of each band by nanospray-MS/MS is summarized
in Figure 2. Band-a was generated in both the control and CB-treated samples on ice upon
treatment with V8 protease, which corresponds to cleavage at the first Glu residue in the N-
terminus of the Hsp90CT construct and removes the His-tag (Fig. 2 and Supplemental Fig.
1). The tryptic peptides identified in each band are described in Figure 2B. Band-c contained
the tryptic peptide spanning residues Glu547-Lys588, but lacked the tryptic/V8 peptides
corresponding to the Leu694-Glu714/Glu715 peptides present in bands-d and -e. Band c also
lacked the tryptic peptide Leu694-Arg727 generated from the C-terminal end of band-b,
suggesting that band-c had a V8 cut between residue Glu714 and Arg727. Regardless of the
exact position of the C-terminal V8 cleavage of band-c, the analysis of the two lower MW
bands (d/e) localizes the CB-bound protease resistant core of Hsp90CT to residues Gly548-
Glu714 (Fig. 2), which is consistent with Neckers earlier studies in support of residues 538–
728. Overall, the data suggests that the binding of chlorobiocin to the Hsp90CT is within a
region that connects the middle domain of Hsp90 to its C-terminal domain, and protects this
region from proteolysis as highlighted in yellow and red in Figure 2D, corresponding to each
monomer of the Hsp90 homodimer.
Identification of the NB binding site in Hsp90's C-terminal Domain
Photolabile derivatives of novobiocin were synthesized for the purpose of identifying the
Hsp90 C-terminal binding site. As noted earlier, the Hsp90 C-terminus is resistant to
proteolysis by trypsin in the presence of chlorobiocin. Similarly, compound 1a also
protected the Hsp90 C-terminus from trypsin proteolysis (Fig. 3), indicating that the
photolabile compound bound Hsp90 in a manner similar to novobiocin and chlorobiocin
(12) (See Supplemental Fig. 1C).
Novobiocin analogues containing a photo-reactive azide moiety placed in the p- (1a/1b) or
m-position (2) were used in lieu of the phenol and prenyl side chain present in NB,
respectively. A recombinant His-tagged Hsp90 C-terminal construct was incubated in the
presence or absence of 1a (27) followed by UV-irradiation. No change in the m/z of
Hsp90CT was detected upon MALDI-TOF analysis of the Hsp90 C-terminus upon UV-
irradiation in the absence of 1a (Fig. 4A), however, in the presence of 1a a new polypeptide
peak (m/z= 25,125) with a mass approximately 545 Da greater than the parental peak (m/z=
24,580) was detected (Fig. 4B), which corresponds to the molecular weight of compound 1a
minus one molecule of N2. To confirm that both the azide-containing molecule and the non-
labeled novobiocin bind to the same location, crosslinking studies were carried out in the
presence of an equimolar concentration of NB and 1a, resulting in a >80% decrease in the
intensity of the 25,125 peak (Fig. 4C), indicating the inhibitors bind competitively. A small
portion of the Hsp90CT was found to be modified by two molecules of 1a, therefore an
experiment was performed with 10-fold lower concentrations of the photolabile inhibitor
(2). A significant reduction in the amount of doubly modified Hsp90CT was observed,
indicating that the first binding event is most specific (Supplemental Fig. 2). To demonstrate
crosslinking specificity, apomyoglobin was irradiated in the presence of 1a, and no
crosslinking was observed, confirming selectivity of these compounds for Hsp90 (Fig. 4D).
Identical crosslinking peaks were detected when 2 was irradiated in the presence of Hsp90,
confirming that azide placement on the benzamide side chain did not affect binding.
To determine the peptide sequence to which the photoactivatable derivative was crosslinked,
control and 1b-crosslinked and 2-crosslinked Hsp90 were digested with trypsin, and the
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masses of the tryptic peptides were analyzed by ultra-high mass accuracy Fourier transform
ion cyclotron resonance (FTICR) mass spectroscopy (mass accuracy of 10 ppm).
Crosslinking of 2 is calculated to increase the theoretical mass of a crosslinked peptide by
527.1613 Da. Analysis of the data identified a peptide corresponding to a mass of ~527 amu
greater than that predicted for an unlabeled peptide sequence, namely: 559-KKQEEK-564 or
560-KQEEKK-565 (1316.6093/~MH1+ 789.4465+527.1540).
As the 2-linked peptide was present as both a +1 (m/z 1316.60) and +2 (m/z 658.80) ion,
MS2 fragmentation of the MH2+ 658.80 and MH1+ 1316.60 ions was carried out to identity
the labeled amino acid (Supplementary Fig. 3, Supplementary Scheme 1A and
Supplementary Table 1B). In addition, the fragmentation pattern of NB and the
underivatized KKQEEK peptide (m/z 789) were analyzed for comparison to the labeled
peptide (Supplementary Fig. 4A and B). Consistent with the fragmentation of novobiocin,
the MS2 spectrum of the 658.80 and 1316.60 ions contained one dominant ion at 1099.47
corresponding to the loss of noviose and the addition of a proton to maintain the ions
positively charged state (Supplementary Fig. 3 and Table 1). An ion at 218.12 corresponding
to positively charged noviose in the MS2 spectrum of the 658.80 ion reiterated the presence
of crosslinked 2 (Supplementary Fig. 5 and Supplementary Table 1C). A peak with an m/z
of 907 amu was predicted for loss of the aminocoumarin ring, however, this was not
observed. In contrast, prominent peaks with m/z of 892.55 (MH1+) and 446.70 (MH2+) were
present and are consistent with the loss of the aminocoumarin ring and a CH3 radical, which
occurs upon rearrangement of the aminocycloheptatriene ring to a pyridine ring (Fig. 5,
Supplementary Scheme 1, Supplementary Fig. 3 and Supplementary Table 1B – See
supplementary materials and methods for a full detailed discussion of the analysis of the MS
data).
Because of the small number of laddering ions observed in the MS2 spectra of the 1312.60
and 658.8 ions, which is common for basic peptides (28), MS2 peaks were selected and
analyzed by MS3 to elucidate the exact peptide sequence. The MS3 spectra of the 1099 peak
resulting from the parental 658.80 MH2+ (Supplementary Fig. 6 and 7 and Supplemental
Table 2) and 1316.60 MH1+ ions (Supplemental Fig. 3 and Supplemental Table 2)
confirmed fragmentation of the 1099 (KK-R2QEEK, Fig.5) and 892 (KK-R3QEEK) ions.
The presence of y4 and y3 ions minus one or two NH3 in the fragmentation pattern of the
1099 ion was consistent with a KKQEEK sequence rather than KQEEKK. The MS3 spectra
of the 389 ion that was present in the MS2 spectra of the 658.80 MH2+ ion indicated a z3
EEK ion (Fig. 5 and Supplemental Table 2), further confirming the peptide sequence.
Together, these results place the photolabile novobiocin derivatives and accordingly,
novobiocin, alongside the peptide 559-KKQEEK-564, and attached directly to K560. This
segment is located in the Hsp90 C-terminus, within the region of the C-terminal fragment
that is protected from proteolysis upon binding to chlorobiocin and novobiocin.
Modeling of NB's conformation
To further refine the NB binding site in Hsp90, conformations of NB co-crystallized with
DNA gyrase/topoisomerase (PDB IDs: 1S14, 1AJ6, 1KIJ) were analyzed. NB was found to
adopt a partially folded conformation in each of these structures. This conformation of NB
was extracted and used to dock into the site of Hsp90 identified via photoaffinity labeling.
Modeling of the Hsp90 NB binding site
The data generated from the photoaffinity labeling studies with NB provides information
regarding the putative binding site of NB. After careful analysis of the homologous peptide
in the full length crystal structure of yeast Hsp90 (538-AEREKEIK-545), it was not clear
Matts et al. Page 4













whether there was a pocket large enough to accommodate NB in the regions flanking this
peptide. Initial attempts to dock novobiocin with this crystal structure were unsuccessful.
However in 2008, the solution structure of the bacterial Hsp90 homologue, HtpG, was
determined by Agard and co-workers using SAXS in concert with molecular modeling (21).
As the full length yeast crystal structure depicts Hsp90 in its closed, clamped conformation,
it was postulated that the extended form, as found in solution, would unveil the C-terminal
binding site. Generation of this model allowed for identification of the C-terminal inhibitor
binding site using the information garnered from the photoaffinity and proteolytic studies.
In an effort to correlate the binding site identified by photoaffinity studies with the open
structure of Hsp90α, a homology model of hHsp90α was generated using the SAXS
structure of HtpG as the template. The homology model of hHsp90α was constructed using
software “Modeller” (29). The solution structure of HtpG (dimer) was used as a template for
building of the model. The modeled structure was subsequently subjected to a molecular
dynamics protocol for further refinement.
Docking of NB into the hHsp90α homology was guided by the following constraints: 1)
Binding of NB to the C-terminal domain protects residues in the N-terminal region of the
construct from proteolysis by V8 protease; 2) proteolytic fingerprinting identified the
peptide KKQEEK in human Hsp90α as the site of crosslinking for photo-reactive NB
derivative; and 3) the bioactive conformation of NB. NB was docked rigidly in the hHsp90α
C-terminus by maintaining a distance constraint of 3.5Å between the hydroxyl of the
noviose and the amide nitrogen of Asn686. A multiple sequence alignment of related
proteins from different organisms indicated two conserved residues adjacent to the
photoaffinity–labeled peptide fragment, Lys538 and Glu562 in hHsp90α. Another residue
that is highly conserved is Lys558 in hHsp90α. Minimization of protein side chains with a
distance constraint of 3.5 Å between NB and residues Asn686, Lys538, and Glu562 and was
carried out while keeping NB and the protein backbone rigid to allow relaxation of the side
chains and minimization of negative interactions. The binding site was subsequently defined
as residues that reside within 8Å of NB and were subjected to minimization while keeping
the rest of the protein and NB fixed to remove unfavorable steric and hydrophobic contacts
and to allow side chains to relax and to facilitate NB alignment in the cavity. The resulting
complex was further refined by a short MD simulation (100ps). This Hsp90α-NB complex
was found to be stable after simulation. (RMSD<2Å) The interactions manifested between
NB and Hsp90α are depicted in Figure 6.
It is evident from Figure 6 B and C that NB is responsible for providing important
interactions with several of the residues present in the binding site. These interactions can be
summarized as follows: 1) A HB interaction between the noviose sugar hydroxyl of
novobiocin and Asn686 and Thr540 of hHsp90α; 2) HB interactions between the oxygen of
the prenylated hydroxylphenyl ring of novobiocin and both Asn590 and Lys560 of
hHsp90α, a residue identified via photoaffinity labeling studies; 3) the CO and -NH of the
noviose carbamate of novobiocin is making a HB interactions with Glu537 and Gln682; 4)
Thr594 provides HB interactions with the oxygen of the glycosidic bond linking the noviose
and coumarin ring; and 5) HB interaction between the noviose methoxy group and Arg591.
Biochemically–guided modeling based on the bacterial homologue of Hsp90, HtpG,
produced a human Hsp90 model that upon further refinement, unveiled the binding mode for
Hsp90 C-terminal inhibitors. This mode of binding explains many of the previously
observed biological and biochemical consequences that result upon Hsp90 C-terminal
inhibition.
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Although there have been previous attempts to model the NB binding site, the results were
not consistent with available biochemical data. Prior models developed for the Hsp90 C-
terminal inhibitor binding site were generated using homology modeling, MD simulations,
and pocket-finder algorithms(30–31). However, using biochemical analyses, affinity
labeling, and homology modeling, we have identified a binding site for C-terminal Hsp90
inhibitors that supports prior biochemical studies.
For example, Neckers and co-workers originally proposed the existence of a binding site in
the Hsp90 C-terminus and determined that NB binding was localized to residues 542–732
(hHsp90α) (9–10). Additionally, it was demonstrated that addition of the C-terminal peptide
667–680 (hHsp90α) reduced Hsp90's ability to bind immobilized NB, and Hsp90 binding to
immobilized NB could be competed with this peptide (9). In the model proposed, this
peptide sequence is located in the α-helix proximal to the sugar binding pocket of NB, and is
important for interactions with the noviose moiety on NB. Consistent with this pocket being
adjacent to the NB binding site, Hartson and coworkers have shown that NB blocks the
AC88 antibody (a monoclonal antibody that recognizes an epitope within the amino acids
668–684 in hHsp90α (32)) from binding Hsp90 (12), thus providing two key pieces of
previously reported biochemical data that further supports the location of this binding site.
Furthermore, ATP binding plays an important role in the conformational reorganization of
Hsp90, in a manner complementary to the dimerization of two Hsp90 monomers at the C-
terminus, which is essential for Hsp90 activity. Once dimerization occurs at the C-terminus,
Hsp90 undergoes a complex conformational cycle that facilitates reorganization and folding
of client proteins(33–34). The C-terminal inhibitor, Coumermycin A1, was shown to disrupt
C-terminal dimerization, and halt the conformational cycle (11). In addition, the protein
folding process involves a multitude of cochaperones and partner proteins. Novobiocin and
related antibiotics have been shown to disrupt interactions with partner proteins that bind
Hsp90 to both the C- and N-terminus, i.e. Cdc37, p23, Hsc70, FKBP52 and PP5(9, 11–12).
C-terminal inhibitors also prevent the binding of small molecules to the N-terminus (10).
Additionally, prior proteolysis experiments and those presented herein with NB and related
family members demonstrate that C-terminal occupation protects Hsp90 from proteolysis by
altering its conformational state. Specifically, NB shields Lys615 and Arg620 from
cleavage. This result can be explained by the examination of Hsp90 in its various
conformational states. Lys615 and Arg620 are solvent exposed on the surface of an alpha
helix in the semi-closed and closed states. However, in the extended form, Lys615 and
Arg620 are shielded by surrounding residues, and hence, are not accessible to proteases.
Interestingly, the pivot point of Hsp90's movement between the middle and C-terminal
domains of Hsp90 (hHsp90α residue 550) is located within close proximity to this binding
site (20–21, 23). Taken together, these data indicate that conformational changes within the
C-terminus occur upon inhibitor binding and cause global conformational changes within
the entire homodimer.
Additionally, Retzlaff and co-workers have demonstrated through mutational analyses that
Hsp90 is regulated by a switch point in its C-terminal domain(35). Mutation of the residue
equivalent to Cys597 in hHsp90α (Ile538 in HtpG) altered Hsp90's ATPase and chaperone
activity, modified N-terminal and C-terminal domain associations, and shifted the
conformational equilibrium of Hsp90 within its ATPase cycle(35). In our model, Cys597
forms part of the NB binding pocket (Fig. 8B/C). Thus, the model suggests that C-terminal
inhibitors have the ability to interact with and stabilize the region around this pivot point,
and prohibiting the global conformational changes required for chaperone activity.
Consequently, upon C-terminal occupation, the Hsp90 machinery is stalled in the open
conformation, which results in protection of Lys615 and Arg620 from proteolysis, hinders
N-terminal ATP hydrolysis, and prevents the binding of N-terminal inhibitors. Once again,
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occupation of this putative binding pocket in the Hsp90 C-terminus can finally explain
previously observed biochemical observations.
In addition, Hugel and coworkers recently determined the dynamics and kinetics of C-
terminal dimerization, whereby the C-terminus is capable of opening in the presence of N-
terminal ligands (i.e. ATP and ATP analogues). Additionally, it was observed that N- and C-
terminal dimerization is intimately related, and that C-terminal dimerization is not required
for N-terminal dimerization. These findings suggest that the C-terminus is in constant flux,
whereby a multitude of conformations exist (24). In the model presented herein, novobiocin
predominantly interacts with one monomer of the Hsp90 homodimer. Together with the data
presented by Hugel, it can be reasoned that small molecule binding of the Hsp90 C-terminus
may occur while this domain is open, preventing dimerization and continuation through the
catalytic cycle. Alternatively, C-terminal inhibitors may bind after dimerization, preventing
occupation of the N-terminal binding pocket by ATP, which is supported by prior studies by
Marcu et. Al. whom demonstrated that novobiocin binding to the C-terminus prevented N-
terminal occupation (10).
Hsp90 C-terminal inhibitors have garnered significant attention during the past decade,
specifically due to problems associated with N-terminal inhibition as observed in the clinic
(36). Structural information regarding the C-terminus, especially the NB binding site, has
been scarce, and attempts at co-crystallization have been unsuccessful. Accordingly,
effective analogue design and data analysis has been hindered. Therefore, we have utilized
photoaffinity labeling and proteolytic studies to identify residues that form the NB binding
site. Through elucidation of the cross-linked peptide and molecular modeling alongside the
reported solution structure of Hsp90, potential binding sites were carefully evaluated. As a
result of these studies and those before us, we are finally able to provide a binding site for
NB and other C-terminal inhibitors that accounts for the biological activities manifested by
NB. This model provides a new paradigm for the development of future Hsp90 inhibitors
that target the C-terminal binding pocket.
METHODS
Characterization of the protease resistant core of Hsp90CT
Recombinant His-tagged Hsp90CT (amino acids 531–732 human Hsp90α) was incubated
with V8 protease at 37 °C in the presence of 800 µM Chlorobiocin or an equivalent volume
of DMSO (vehicle control). Protease resistant bands were separated by SDS-PAGE, excised,
digested with trypsin and analyzed by LC-MS/MS as described in the “Supplementary
Methods”.
Identification of the NB binding site in Hsp90CT
After optimization of crosslinking conditions with 1 (Fig. 3), recombinant His-tagged
Hsp90CT was exposed to four flashes of 184 μJ of UV radiation in the presence of 0.5 mM
of either 1, 2 or DMSO (vehicle control), followed by digestion of the samples with trypsin.
The tryptic peptides were subjected to capillary LC-MS/MS experiments using tandem
LTQ-FT Mass Spectrometer (ThermoFinnigan) under conditions described previously(37),
followed by data analysis as described in “Supplementary Methods”.
Refinement of Hsp90α Structure
The sequence of hHsp90α was used to search similar sequences using NCBI blast.(38) A
multiple sequence alignment was performed using ClustalW with default parameters to align
these sequences and to identify structurally conserved regions and important residues.(39)
The minimization of the side chains was performed using Sybyl molecular modeling
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software.(40) Initially, the protein was held fixed except for the binding site residues
(residues falling within 8Å of novobiocin molecule). Thereafter, all side chains and the
binding site were kept free and minimization was done. All the minimization was done until
the RMS gradient of 0.05 Kcal/MolÅ was obtained using AMBER9 force field.
Molecular Dynamics Protocol
Hsp90α-NB was prepared for simulation in AMBER9 package while the simulation was
done using NAMD software.(41) The force field parameters for NB were calculated by
antechamber module of AMBER9. The HtpG-NB complex was solvated in a box of water
with buffering distance of 10 Å; assuming normal charge states of ionizable groups
corresponding to pH 7, sodium (Na+) and chloride (Cl−) counter-ions were added to achieve
charge neutrality and to mimic biological environment more closely. All Na+ and Cl− ions
were placed at least 8 Å away from any protein atoms and from each other. The system was
subjected to initial minimization for 20000 steps (40ps) keeping protein backbone fixed
which was followed by 20000 steps (40ps) of minimization without fixing anything (to
allow system to relax freely). Further details of the molecular dynamics protocol used to
compute the final model and Homology modeling of the NB binding site in Hsp90α are
presented in “Supplemental Materials and Methods”
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Representative Hsp90 C-terminal inhibitors
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V8 protease resistant core of Hsp90's C-terminal Domain. a) Protease-resistance of
chlorobiocin bound Hsp90CT. Hsp90CT was incubated in the presence (lanes 2–4 & 6–8) of
V8 protease with the addition of DMSO (vehicle control: lanes 1–4) or 800 mM
chlorobiocin (lanes 5–8) for 0 min (lanes 2 & 6), 15 min (lanes 3 & 7) or 30 min (lanes 4 &
8). Lanes 1 and 5: Undigested full length Hsp90CT (-FL). Protease resistant bands a–e as
indicated. b) Table including the sequences identified and boundaries for each band
identified after proteolysis and SDS-PAGE. Red and blue rows correspond to the protease
resistant core and flanking regions, respectively. c) Sequence of the Hsp90 C-terminus.
Lower and upper case letters indicate residues from the His-tag and Hsp90 C-terminus,
respectively. Vertical lines (∣) indicate important cleavage sites that define the boundaries of
bands a–e. Peptide bands a–e are depicted by left and right arrows denoting N- and C-
termini of these bands. Bold and red residues comprise the chlorobiocin induced Hsp90 CT
protease resistant core. d) Hsp90 C-terminus, important cleavage sites labeled (spheres); red
and yellow cartoons provide the protease resistant core from each Hsp90 monomer, while
blue cartoon indicates upstream residues not part of protease resistant core.
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Figure 3. Novobiocin derivatives used in photoaffinity labeling studies
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Figure 4. Crosslinking of 1 to Hsp90CT is specific
Hsp90CT (a–c) or apomyogobin (d) were UV irradiated as described under “Materials and
Methods” in the presence of a) DMSO, b & d) 5 mM 1a, c) 5 mM 1a plus 5 mM NB and
analyzed by MALDI-TOF mass spectrometry.
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Figure 5. Laddering ions generated from the 2-crosslinked peptides
R1, R2, and R3 represent the major fragmentation products generated from crosslinking
with 2.
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Figure 6. Modeled structure of the Novobiocin binding site in hHsp90α
a) The Hsp90α homology model homodimer and the C-terminal binding site with NB
(spheres) docked at the interface of two monomers (blue and yellow) b) close-up of NB
(grey sticks) docked in Hsp90α homology model, the crosslinked fragment (lines) and
predicted hydrogen bonds (dashes) are depicted in magenta and c) close-up of NB noviose
(grey sticks) docked in Hsp90α homology model, predicted hydrogen bonds (dashes) are
represented in magenta, d) surface representation of Hsp90α homology model CT binding
site with NB (grey sticks) docked. Only one molecule of NB is shown to be bound to Hsp90
homodimer, an equivalent binding site contained on the other monomer has not been shown
for clarity.
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